Business
PDS collaborator awarded grant for Versamune
PDS collaborator awarded grant for Versamune.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n RNS Number : 9944S\n NetScientific PLC\n 14 July 2020\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\" or the \"Company\")\n \n \n PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine\n \n \n NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq: PDSB) today announced that \n PDS Biotech collaborator, Professor J. Woodward of the University of Kentucky School of Medicine, has been awarded a grant from the National Institute of Allergy and Infectious Diseases' (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to progress development of a Versamune®-based universal influenza vaccine.\n \n \n The key objective of the NIAID's CIVICs program is to develop more durable, broadly protective, and longer-lasting vaccines effective against multiple strains of influenza, specifically including pandemic strains. Under the award, PDS Biotech will continue development of its PDS0202 vaccine program, which combines Versamune® with novel influenza vaccine antigens, with a goal of rapidly progressing into a human clinical trial. Preclinical development studies will be performed at three sites: PDS Biotech's Princeton, NJ laboratories, The University of Kentucky School of Medicine, and the CIVICs Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP).\n \n \n NetScientific holds 7.18% of PDS' undiluted share capital.\n \n \n Dr. Ilian Iliev, Chief Executive Office of the Company said: \n \"We are pleased that PDS Biotechnology continues to expand the exploitation of the Versamune platform technology for vaccines applications, in this case for the development of a universal influenza vaccine through their collaboration with the University of Kentucky School of Medicine. This follows the announcement on 18th June of a collaboration with Brazil's Farmacore on the development of a Versamune®-based vaccine aimed at preventing COVID-19 infection.\"\n \n \n The full details of the announcement are set out below and can be found he\n re: \n \n https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/405-iotechollaboratorrantedwardtoccelerate20200714\n \n \n &...